Finally, a successful adjuvant therapy for high-risk melanoma.
Balch
C M
CM
Buzaid
A C
AC
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011379:Prognosis; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate
D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins